Menu ×

The Human Papillomavirus (HPV) Vaccine Market to Expand on the Back of Increasing Prevalence of Various Cancers & Increasing Participation by People in Initiatives with USD 3.9 Billion by 2027

  • Text Size:

According to a recently published report by Research Nester on Human Papillomavirus (HPV) Vaccine Market: Global Demand Analysis & Opportunity Outlook 2027” delivers detailed overview of the human papillomavirus vaccine market in terms of market segmentation by valence, by indication, by distribution channel and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The global human papillomavirus vaccine market is valued at USD 2.4 Billion in 2018 and is expected to reach USD 3.9 Billion by 2027. The market is anticipated to record a CAGR of around 5.3% over the forecast period i.e. 2019-2027. The market is segmented by valence, indication & distribution channel. The market is segmented by valence into quadrivalent & non-avalent, bivalent and others. The market is further segmented by indication into cervical cancer, anal cancer, penile cancer, vulvar cancer, oropharyngeal cancer, genital warts and others. On the basis of distribution channel, the market is segmented by physicians, distributors, government entities, public& private alliances and others.

The market has high unmet needs which is expected to create huge opportunities for the major existing market players and new entrants. There has been huge investment in R&D that has led to the growth of the HPV vaccines market during the forecast period. Various private and public alliances such as GAVI have initiated to provide vaccination to people in developing countries.

Increased Prevalence of Various Cancers and Awareness

According to CDC, HPV is the most common disease transmitted in the U.S. About 14 million people every year are infected through HPV. About 90% of anal and cervical cancers, 70% of vulvar and vaginal cancers and 60% of penile cancers are caused by human papillomavirus infection. Moreover, there has been increased participation by the people of Australia in National Papillomavirus Vaccination Program. Among young women and girls in Australia, more than 9 million doses of HPV vaccines have already been given and this initiative led to 90% decrease in genital warts among heterosexual men and women under the age of 21 years and 50% (approx.) decrease in high grade cervical abnormalities in girls under the age of 18 years. These factors are expected to drive the growth of the HPV vaccine market during the forecast period.

However, high price of the vaccines and its variations are common which may not be affordable by the common people. Additionally, government of various countries are significantly concerned about the funding of such vaccines in the long term and this is expected to operate as a key restraint to the growth of human papillomavirus (HPV) vaccine market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the human papillomavirus vaccine market which includes company profiling of GlaxoSmithKline Plc., Merck & Co., Inc., and Sanofi, Johnson & Johnson, AstraZeneca, Serum Institute of India Pvt. Ltd. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the human papillomavirus vaccine market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved